Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

Autor: Mónica Jorge Fernández, Maria Luz Pellon Augusto, J. Méndez, Ana Montes, Juan de la Cámara Gómez, Mercedes Salgado Fernández, Margarita Reboredo Lopez, Nieves Martinez Lago, Guillermo Alfonso Quintero Aldana, Paula González Villaroel, Marta Covela Rúa, Jesús García Gómez, Begoña Graña Suárez

Publikováno v: Cancer Medicine

Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI‐afliber

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae65e3bd50f9a60867938d42f4c8e9d0
http://europepmc.org/articles/PMC6434192

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

Autor: José Federico González González, Jaime Feliu, P. Vicente, Esther Casado Gonzalez, Guillermo Lopez-Vivanco, Ana Montes, Carmen Garcia Piernavieja, Teresa Macarulla, Irene Gonzalez Cebrian, A. Muñoz, Manuel Valladares-Ayerbes, Mónica Jorge Fernández, Juan Ignacio Delgado-Mingorance, Bartomeu Massuti, Ana Albero, Rebeca Mondéjar Solís, Guillermo Quintero-Aldana

Publikováno v: CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Digital.CSIC. Repositorio Institucional del CSIC

[Purpose] To evaluate the health-related quality of life (HRQoL), global health status (GHS), and deterioration-free survival of an elderly population (> 70 years) with unresectable locally advanced (LAPC) or metastatic pancreatic cancer (mPC) treate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a672bc10eeb5fd2ed44a11fb2bed1c7c
https://pubmed.ncbi.nlm.nih.gov/33452559

Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis

Autor: Lidia Vázquez Tuñas, Guillermo Alfonso Quintero Aldana, Paula Gonzalez Villarroel, Manuel Valladares Ayerbes, Mercedes Salgado Fernández, Ana Fernández Montes, Mónica Jorge Fernández, Juan de la Cámara Gómez

Publikováno v: Journal of Cancer Research and Therapeutics, Vol 13, Iss 2, Pp 240-245 (2017)

Background: Recent studies support the use of gemcitabine and nab-paclitaxel in adults with locally advanced unresectable or metastatic pancreatic adenocarcinoma although insufficient data are available on prognostic and predictive markers of respons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788375f5724453113cd054d9d2f2ffa7
http://www.cancerjournal.net/article.asp?issn=0973-1482

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study

Autor: Guillermo Alfonso Quintero Aldana, Teresa Macarulla, Carlos García Girón, Jaime Feliu Batlle, Bartomeu Massuti, R. Mondejar, Carmen Garcia Piernavieja, Ana Albero, F. Gonzalez, Mónica Jorge Fernández, Manuel Valladares-Ayerbes, J. Ignacio Delgado Mingorance, Guillermo Lopez-Vivanco, Ana Montes, Pilar Vicente, Irene Gonzalez Cebrian, Esther Casado

Publikováno v: Journal of Clinical Oncology. 38:4615-4615

4615 Background: FOLFIRINOX and nab-paclitaxel plus gemcitabine (nab-P+G) are the standard of care in the first-line treatment of mPC patients (pt) with good performance status. However, no standards of care exist for elderly ( > 70 years) pt as they

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a52bbab2000efe596a2abbc5f2bedd2b
https://doi.org/10.1200/jco.2020.38.15_suppl.4615

The prognostic value of systemic inflammatory factors in BRAF (V600E) mutant metastatic colorectal cancer (mCRC)

Autor: Begoña Graña Suárez, Juan de la Cámara Gómez, Carlos Méndez Méndez, Elena Gallardo Martin, Nieves Martinez Lago, Maria Luz Pellon Augusto, Margarita Reboredo Lopez, Antia Cousillas Castiñeira, Sonia Candamio Folgar, Carlos Grande Ventura, Guillermo Alfonso Quintero Aldana, Paula Gonzalez Villarroel, Elena Brozos Vazquez, Mónica Jorge Fernández, Marta Covela Rúa, Ana Montes, Francisca Vázquez Rivera, Marta Carmona Campos, Mercedes Salgado Fernández, Alberto Carral Maseda

Publikováno v: Journal of Clinical Oncology. 37:622-622

622 Background: Multiple studies have reported prognostic association of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLT) and albumin levels including patients with early and advanced metastatic colorectal cancer. However, it

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dca78e5125cb930a836192fbfd79fcbf
https://doi.org/10.1200/jco.2019.37.4_suppl.622